Viracta Therapeutics Announces Wind Down of Operations
February 05 2025 - 5:00PM
Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage
precision oncology company focused on the treatment and prevention
of virus-associated cancers that impact patients worldwide,
announced today that the Company has terminated its employees and
will wind down operations. The company is also exploring potential
strategic alternatives for its development programs.
The board of directors appointed Craig R. Jalbert, age 63, as
the Company’s CEO, President, CFO, Treasurer and Corporate
Secretary, and sole member of the board to implement the wind down.
Mr. Jalbert has served as a principal of the Foxborough,
Massachusetts accounting firm of Verdolino & Lowey, P.C. since
1987. For over 30 years he has focused his practice in distressed
businesses and has served, and continues to serve, in the
capacities of officer and director for numerous firms in their
wind-down phases.
Forward-Looking StatementsThis communication
contains "forward-looking" statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including,
without limitation, statements regarding the Company’s plans to
wind down operations and explore potential strategic alternatives.
Risks and uncertainties related to Viracta that may cause actual
results to differ materially from those expressed or implied in any
forward-looking statement include, but are not limited to, the
timing and prospects of the wind down process and the likelihood
and viability of any potential strategic alternatives.
Additional risks and uncertainties that could cause actual
outcomes and results to differ materially from those contemplated
by the forward-looking statements are included under the caption
"Risk Factors" and elsewhere in Viracta's reports and other
documents that Viracta has filed, or will file, with the SEC from
time to time and available at www.sec.gov.
The forward-looking statements included in this communication
are made only as of the date hereof. Viracta assumes no obligation
and does not intend to update these forward-looking statements,
except as required by law or applicable regulation.
Contact Information:Verdolino & Lowey,
P.C.124 Washington Street, Suite 101Foxborough, MA 02035Phone:
508-543-1720Viracta@vlpc.com
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From Feb 2025 to Mar 2025
Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
From Mar 2024 to Mar 2025